Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

322 ARTÍCULOS , VIENDO DEL 31 AL 45

Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease

Fu AL, Zhou CY, Chen X.

Neuropharmacology. 2010 Mar-Apr;58(4-5):722-9. doi: 10.1016/j.neuropharm.2009.12.020. Epub 2010 Jan 5.

Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence

Albani D, Polito L, Forloni G.

J Alzheimers Dis. 2010;19(1):11-26. doi: 10.3233/JAD-2010-1215.

Why vitamin E therapy fails for treatment of Alzheimer's disease

Brewer GJ.

J Alzheimers Dis. 2010;19(1):27-30. doi: 10.3233/JAD-2010-1238.

Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease

Wang L, Harms MP, Staggs JM, Xiong C, Morris JC, Csernansky JG, Galvin JE.

Arch Neurol. 2010 Jan;67(1):99-106. doi: 10.1001/archneurol.2009.292.

Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant

Li QY, Gordon MN, Chackerian B, Alamed J, Ugen KE, Morgan D.

J Neuroimmune Pharmacol. 2010 Mar;5(1):133-42. doi: 10.1007/s11481-009-9183-1.

Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch

Sadowsky C, Perez JA, Bouchard RW, Goodman I, Tekin S.

CNS Neurosci Ther. 2010 Spring;16(1):51-60. doi: 10.1111/j.1755-5949.2009.00119.x.

[Alzheimer's disease, cerebral blood flow, and nitric oxide]

Toda N, Ayajiki K.

Nihon Yakurigaku Zasshi. 2010 Jan;135(1):20-4. doi: 10.1254/fpj.135.20.

Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C.

AAPS J. 2010 Jun;12(2):117-29. doi: 10.1208/s12248-009-9164-6. Epub 2010 Jan 15.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

Discovery of notch-sparing gamma-secretase inhibitors

Augelli-Szafran CE, Wei HX, Lu D, Zhang J, Gu Y, Yang T, Osenkowski P, Ye W, Wolfe MS.

Curr Alzheimer Res. 2010 May;7(3):207-9. doi: 10.2174/156720510791050920.

New methods to explore marine resources for Alzheimer's therapeutics

Williams P, Sorribas A, Liang Z.

Curr Alzheimer Res. 2010 May;7(3):210-3. doi: 10.2174/156720510791050812.

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials

Sadowsky CH, Farlow MR, Meng X, Olin JT.

Int J Clin Pract. 2010 Jan;64(2):188-93. doi: 10.1111/j.1742-1241.2009.02253.x.

Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?

Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X.

Mol Neurobiol. 2010 Jun;41(2-3):87-96. doi: 10.1007/s12035-009-8095-7. Epub 2010 Jan 27.

Current treatment and recent clinical research in Alzheimer's disease

Neugroschl J, Sano M.

Mt Sinai J Med. 2010 Jan-Feb;77(1):3-16. doi: 10.1002/msj.20165.

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease

Grossberg GT, Sadowsky C, Olin JT.

Int J Clin Pract. 2010 Apr;64(5):651-60. doi: 10.1111/j.1742-1241.2009.02330.x. Epub 2010 Jan 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias